JP2015500225A - 癌の併用処置 - Google Patents
癌の併用処置 Download PDFInfo
- Publication number
- JP2015500225A JP2015500225A JP2014543977A JP2014543977A JP2015500225A JP 2015500225 A JP2015500225 A JP 2015500225A JP 2014543977 A JP2014543977 A JP 2014543977A JP 2014543977 A JP2014543977 A JP 2014543977A JP 2015500225 A JP2015500225 A JP 2015500225A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutically acceptable
- azd5363
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 75
- 201000011510 cancer Diseases 0.000 title claims abstract description 65
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 claims abstract description 117
- 150000003839 salts Chemical class 0.000 claims abstract description 97
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229960004671 enzalutamide Drugs 0.000 claims abstract description 39
- 229960004103 abiraterone acetate Drugs 0.000 claims abstract description 34
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims abstract description 33
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims abstract description 28
- 229960000853 abiraterone Drugs 0.000 claims abstract description 26
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims abstract description 23
- 229960000997 bicalutamide Drugs 0.000 claims abstract description 23
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- JMEYDSHPKCSIJC-UHFFFAOYSA-N 1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCOC1=CC=C(C2CCN(CC2)C=2CCC=3N(C(=NN=3)C(F)(F)F)N=2)C=C1 JMEYDSHPKCSIJC-UHFFFAOYSA-N 0.000 claims abstract description 15
- 108010080146 androgen receptors Proteins 0.000 claims abstract description 13
- 230000011664 signaling Effects 0.000 claims abstract description 12
- 150000002148 esters Chemical class 0.000 claims abstract description 11
- 239000000651 prodrug Substances 0.000 claims abstract description 11
- 229940002612 prodrug Drugs 0.000 claims abstract description 11
- 102000001307 androgen receptors Human genes 0.000 claims abstract 5
- 239000003814 drug Substances 0.000 claims description 20
- 206010060862 Prostate cancer Diseases 0.000 claims description 17
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 17
- 239000002552 dosage form Substances 0.000 claims description 17
- 239000003085 diluting agent Substances 0.000 claims description 15
- 238000011284 combination treatment Methods 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 238000009097 single-agent therapy Methods 0.000 description 14
- 230000034994 death Effects 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 206010027476 Metastases Diseases 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 102100032187 Androgen receptor Human genes 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013066 combination product Substances 0.000 description 3
- 229940127555 combination product Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- -1 abiraterone acetate Chemical compound 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
AZD5363または薬学的に許容しうるその塩;
と、以下から選択されるアンドロゲン受容体シグナル伝達モジュレーター:
MDV−3100;
AZD3514;
アビラテロンもしくはそのエステルプロドラッグ;および
ビカルタミド;
または薬学的に許容しうるそれらの塩。
AZD5363または薬学的に許容しうるその塩;
と、以下から選択されるアンドロゲン受容体シグナル伝達モジュレーター:
MDV−3100;
AZD3514;
アビラテロンもしくは酢酸アビラテロン;および
ビカルタミド;
または薬学的に許容しうるそれらの塩。
AZD5363または薬学的に許容しうるその塩;
と、以下から選択されるアンドロゲン受容体シグナル伝達モジュレーター:
MDV−3100;
AZD3514;
酢酸アビラテロン;および
ビカルタミド;
または薬学的に許容しうるそれらの塩。
AZD5363または薬学的に許容しうるその塩;
と、以下から選択されるアンドロゲン受容体シグナル伝達モジュレーター:
MDV−3100;
AZD3514;
アビラテロン;および
ビカルタミド;
または薬学的に許容しうるそれらの塩。
(i)AZD5363または薬学的に許容しうるその塩を、薬学的に許容しうる希釈剤または担体と共同して含む薬学的組成物;および
(ii)‘組み合わせの他のパートナー’または薬学的に許容しうるその塩を、薬学的に許容しうる希釈剤または担体と共同して含む薬学的組成物。
既に上記したように、“組み合わせの他のパートナー”について言及する場合、文脈上そうではないことが必要でない限り、これは、本発明のさまざまなさらなる具体的態様を提供するために、MDV−3100;AZD3514;アビラテロンもしくはそのエステルプロドラッグ(例えば酢酸アビラテロン);またはビカルタミドの1つをさす。
a)第1の単位剤形にあるAZD5363または薬学的に許容しうる塩;
b)第2の単位剤形にある‘組み合わせの他のパートナー’(先に定義したような)または薬学的に許容しうるその塩;
c)前記第1および第2の剤形を入れるための容器手段;ならびに所望により
d)使用説明書。
a)第1の単位剤形にあるAZD5363または薬学的に許容しうるその塩;
b)第2の単位剤形にある‘組み合わせの他のパートナー’(先に定義したような)または薬学的に許容しうるその塩;ならびに
c)前記第1および第2の剤形を入れるための容器手段;ならびに所望により
d)使用説明書。
図のリスト
図1: AZD5363とMDV3100の併用による、LNCaP細胞における細胞成長の阻害および増大した細胞死。
図2: AZD5363とMDV3100の併用による、VCAP細胞における細胞成長の阻害および増大した細胞死。
図3: AZD5363とビカルタミドの併用による、LNCaP異種移植片モデルにおける増大した抗腫瘍効果。
図1は、単剤療法としてのAZD5363または0.1μM〜10μMの異なる5濃度のMDV−3100との組み合わせでのAZD5363の各濃度に対する、LNCaP細胞における平均成長%を示す(n=3)。正の値(0〜100%)は増殖抑制効果を示し、負の値(0〜−100%)は細胞致死を示している。これらの結果は、AZD5363が単剤療法としてLNCaP細胞の成長を阻害して細胞死を引き起こすことができ、この効果がMDV−3100との処置により相乗的に高められることを示している。
図2は、単剤療法としてのAZD5363または0.1μM〜10μMの5濃度のMDV−3100との組み合わせでのAZD5363の各濃度に対する、VCAP細胞における平均成長%を示す(n=3)。正の値(0〜100%)は増殖抑制効果を示し、負の値(0〜−100%)は細胞致死を示している。これらの結果は、AZD5363が単剤療法としてVCAP細胞の成長を阻害することができ、この効果がMDV−3100との処置により相乗的に高められることを示している。
図3は、AZD5363およびビカルタミドが関与する単剤療法および併用療法で処置したときのマウスにおける平均腫瘍体積を示している。図に明示していないが、図に示した“AZD5363+ビカルタミド”のデータは、AZD5363単独およびビカルタミド単独に関し図に示したものと同じ投与量およびスケジュール、すなわち、100mg/kg、1日2回(bd)、5日間投与、2日間投与なしのAZD5363を、50mg/kg、1日2回のビカルタミドと組み合わせることを包含する。
AZD5363とMDV−3100の組み合わせ
LNCaPおよびVCAP前立腺腫瘍細胞株(American Tissue Culture Collection)を、10%FCSおよび2mM L−グルタミンを補給したRMPI中で日常的に培養した。単剤療法として、または組み合わせでのAZD5363およびMDV−3100の細胞成長に対する効果を決定するために、Sytox Green終点を用いて増殖アッセイを実施して、5日後の生細胞数を測定した。簡単に説明すると、LNCAPまたはVCAP細胞を、384ウェルプレートに1ウェルあたりそれぞれ1500または2500細胞の密度で播種し、一晩放置して付着させた。その後、6×6のマトリックスフォーマットで、細胞に、AZD5363(0.01〜1μM)、MDV−3100(0.1〜10μM)または各作用物質の組み合わせを、濃度を次第に増加させて投薬した。化合物に5日間暴露した後、TBS−EDTA(TBS=トリス緩衝食塩水、EDTA=エチレンジアミン四酢酸)緩衝液で希釈したSytox Green核酸染料(Invitrogen)を0.13mmol/Lの最終濃度で細胞に加え、Acumen Explorerを用いて死亡細胞数を検出した。その後、サポニン(最終濃度0.03%、TBS−EDTA緩衝液で希釈)の添加により細胞を透過化し、一晩インキュベートし、全細胞総数を測定した。その後、生細胞総数を、1ウェルあたりの死亡細胞数を全細胞数から差し引くことにより決定した。実験開始時の生細胞数(Tz)を示すため、したがって、処置計画が細胞死をもたらしたか否かを示すために、投薬前の測定を行った。データは、以下のNCIの式を用いて成長%として表す:
Ti>/=Tzである場合の濃度では[(Ti−Tz)/(C−Tz)]×100
Ti<Tzである場合の濃度では[(Ti−Tz)/Tz]×100
これに関し、‘Tz’はゼロ時間目の生細胞数を表し、‘C’は対照の成長を表し、‘Ti’は各投薬計画の存在下での生細胞数を表す。この式により、−100%〜+100%の成長百分率が得られる。負の評点は細胞致死に関し、正の評点は増殖抑制に関する。データを図1および図2に表す。薬剤の組み合わせの相乗効果は、C.Harbronにより記載されている統一アプローチ(Stat.Med.2010年7月20日;29(16):1746−56)を用いて評価した。
3つの実験に関する組み合わせ指数(combination index)およびp値
<1の組み合わせ指数は相乗効果を示す。‘p値’は統計的有意性に関連する。
AZD5363とビカルタミドの組み合わせは、in vivoでの去勢抵抗性前立腺癌の異種移植片モデルにおいて、単剤療法より優れた腫瘍成長阻害をもたらす:LNCaP前立腺癌細胞(PTENヌル、アンドロゲン受容体陽性)を雄の無胸腺ヌードマウスの側腹部に移植した。腫瘍成長および血清中の前立腺特異抗原(PSA)の濃度をモニタリングした。血清PSAが50ng/mLを超えたら、マウスを去勢した。マウスを無作為に群に分け、PSA濃度が少なくとも50ng/mLに回復したときに処置を開始した。AZD5363単剤療法での処置(100mg/kg 1日2回、5日間投与、2日間投与なし)は腫瘍体積の56%阻害をもたらし、ビカルタミド単剤療法での処置(50mg/kg、1日1回)は腫瘍体積の42%阻害をもたらした。組み合わせたものはさらに著しく効果的であり、腫瘍体積の85%阻害をもたらした。このデータは、AZD5363とアンドロゲンアンタゴニストであるビスカルタミドとの組み合わせが十分に耐容され、単剤療法での同等用量の各化合物より優れた効果をもたらすことを示している。結果を図3に示す。
Claims (17)
- 以下を含む組み合わせ:
AZD5363または薬学的に許容しうるその塩;
と、以下から選択されるアンドロゲン受容体シグナル伝達モジュレーター:
MDV−3100;
AZD3514;
アビラテロンもしくはそのエステルプロドラッグ;および
ビカルタミド;
または薬学的に許容しうるそれらの塩。 - AZD5363または薬学的に許容しうるその塩と、MDV−3100であるアンドロゲン受容体シグナル伝達モジュレーターとを含む、請求項1に記載の組み合わせ。
- AZD5363または薬学的に許容しうるその塩と、アビラテロンもしくは酢酸アビラテロンまたは薬学的に許容しうるその塩であるアンドロゲン受容体シグナル伝達モジュレーターとを含む、請求項1に記載の組み合わせ。
- 医薬として用いるための、請求項1〜3のいずれか一項に記載の組み合わせ。
- 癌の処置における医薬として用いるための、請求項1〜3のいずれか一項に記載の組み合わせ。
- 癌が前立腺癌である、請求項5に記載の組み合わせ。
- 癌が去勢抵抗性前立腺癌である、請求項5に記載の組み合わせ。
- 以下を含むキット:
a)第1の単位剤形にあるAZD5363または薬学的に許容しうる塩;
b)第2の単位剤形にあるMDV−3100;
c)前記第1および第2の剤形を入れるための容器手段;
ならびに、所望により使用説明書。 - 以下を含むキット:
a)第1の単位剤形にあるAZD5363または薬学的に許容しうる塩;
b)第2の単位剤形にあるアビラテロンもしくは酢酸アビラテロンまたは薬学的に許容しうるその塩;
c)前記第1および第2の剤形を入れるための容器手段;
ならびに、所望により使用説明書。 - キットが癌の処置に用いるためのものである、請求項6または7に記載のキット。
- キットが前立腺癌の処置に用いるためのものである、請求項6または7に記載のキット。
- キットが去勢抵抗性前立腺癌の処置に用いるためのものである、請求項10に記載のキット。
- 癌の処置で用いるために、
薬学的に許容しうる希釈剤または担体と一緒であってもよい有効量のAZD5363または薬学的に許容しうるその塩;
および、薬学的に許容しうる希釈剤または担体と一緒であってもよい有効量のMDV−3100を、
そのような治療的処置を必要としているヒトなどの温血動物に同時、個別または逐次的に投与することを含む、併用処置。 - 癌の処置で用いるために、
薬学的に許容しうる希釈剤または担体と一緒であってもよい有効量のAZD5363または薬学的に許容しうるその塩;
および、薬学的に許容しうる希釈剤または担体と一緒であってもよい有効量のアビラテロンもしくは酢酸アビラテロンまたは薬学的に許容しうるその塩を、
そのような治療的処置を必要としているヒトなどの温血動物に同時、個別または逐次的に投与することを含む、併用処置。 - 前立腺癌を処置するための請求項13または14に記載の併用処置。
- 癌が去勢抵抗性前立腺癌である、請求項13または14に記載の併用処置。
- 癌が転移性去勢抵抗性前立腺癌である、請求項13または14に記載の併用処置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564975P | 2011-11-30 | 2011-11-30 | |
US61/564,975 | 2011-11-30 | ||
PCT/GB2012/052969 WO2013079964A1 (en) | 2011-11-30 | 2012-11-30 | Combination treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015500225A true JP2015500225A (ja) | 2015-01-05 |
JP2015500225A5 JP2015500225A5 (ja) | 2016-01-21 |
JP6309454B2 JP6309454B2 (ja) | 2018-04-11 |
Family
ID=47295082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014543977A Active JP6309454B2 (ja) | 2011-11-30 | 2012-11-30 | 癌の併用処置 |
Country Status (25)
Country | Link |
---|---|
US (2) | US20140329786A1 (ja) |
EP (1) | EP2785349B2 (ja) |
JP (1) | JP6309454B2 (ja) |
KR (1) | KR102035361B1 (ja) |
CN (1) | CN103945849B (ja) |
AU (1) | AU2012321110B2 (ja) |
CA (1) | CA2856646C (ja) |
CY (1) | CY1122624T1 (ja) |
DK (1) | DK2785349T4 (ja) |
ES (1) | ES2762250T5 (ja) |
FI (1) | FI2785349T4 (ja) |
HK (1) | HK1202253A1 (ja) |
HR (1) | HRP20191982T4 (ja) |
HU (1) | HUE046667T2 (ja) |
IL (1) | IL232530B (ja) |
LT (1) | LT2785349T (ja) |
MX (1) | MX367640B (ja) |
MY (1) | MY175800A (ja) |
PL (1) | PL2785349T5 (ja) |
PT (1) | PT2785349T (ja) |
RS (1) | RS59493B2 (ja) |
RU (1) | RU2640485C2 (ja) |
SG (1) | SG11201401471PA (ja) |
SI (1) | SI2785349T2 (ja) |
WO (1) | WO2013079964A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
WO2010040020A1 (en) | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
MX355915B (es) | 2010-02-16 | 2018-05-04 | Aragon Pharmaceuticals Inc | Moduladores del receptor de androgenos y usos de los mismos. |
JP6100700B2 (ja) | 2011-01-11 | 2017-03-22 | ノバルティス アーゲー | 組合せ |
AU2012358219A1 (en) * | 2011-12-22 | 2014-07-10 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using P13K/mTOR inhibitors |
AU2013204533B2 (en) * | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
EA202190820A1 (ru) * | 2012-09-26 | 2021-10-29 | Арагон Фармасьютикалз, Инк. | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
CN109674801A (zh) * | 2013-10-01 | 2019-04-26 | 诺华股份有限公司 | 组合 |
AU2014330780B2 (en) * | 2013-10-01 | 2017-05-25 | Novartis Ag | Enzalutamide in combination with Afuresertib for the treatment of cancer |
US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
ES2900149T3 (es) | 2016-07-21 | 2022-03-16 | Hadasit Med Res Service | Combinaciones que comprenden antagonistas o inhibidores de AR para su uso en el tratamiento del glioblastoma |
JP7048106B2 (ja) * | 2016-12-16 | 2022-04-05 | カンプ・バイオファーマスーティカルズ、リミテッド | 組み合わせ、その用途及び処置方法 |
CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
CN111107852A (zh) * | 2017-09-22 | 2020-05-05 | 分散技术有限责任公司 | 阿比特龙-环状寡聚体药物制剂及其形成和施用方法 |
WO2019078920A1 (en) | 2017-10-16 | 2019-04-25 | Aragon Pharmaceuticals, Inc. | ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER |
CN108486041A (zh) * | 2018-03-28 | 2018-09-04 | 华南农业大学 | PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010092371A1 (en) * | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
JP2011500547A (ja) * | 2007-10-11 | 2011-01-06 | アストラゼネカ アクチボラグ | プロテインキナーゼb阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637271A (ja) | 1963-04-04 | 1900-01-01 | ||
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
DK0633893T3 (da) | 1992-03-31 | 2000-04-17 | Btg Int Ltd | 17-Substituerede steroider, der er nyttige ved cancerbehandling |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
AU715202B2 (en) | 1996-04-03 | 2000-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
BRPI9810945B8 (pt) | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas |
HUP0002956A3 (en) | 1997-08-05 | 2002-01-28 | Pfizer Prod Inc | Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
PL345906A1 (en) | 1998-06-04 | 2002-01-14 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
YU83302A (sh) | 2000-06-26 | 2005-09-19 | Pfizer Products Inc. | Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi |
BR0113585A (pt) | 2000-08-31 | 2003-07-29 | Hoffmann La Roche | Derivados quinazolina como antagonistas adrenérgicos alfa-1 |
NZ525885A (en) | 2000-12-01 | 2005-01-28 | Osi Pharm Inc | Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US20020182204A1 (en) | 2001-03-23 | 2002-12-05 | Marie-Christine Bissery | Combination of a taxane and a cyclin-dependent kinase |
IL162884A0 (en) | 2002-01-07 | 2005-11-20 | Eisai Co Ltd | Deazapurines and uses thereof |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
MEP16308A (en) | 2002-05-17 | 2010-06-10 | Aventis Pharma Sa | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
TW200410688A (en) | 2002-06-26 | 2004-07-01 | Ono Pharmaceutical Co | Therapeutics for diseases from vasoconstriction or vasodilatation |
US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
JP2006503826A (ja) | 2002-09-06 | 2006-02-02 | スミスクライン・ビーチャム・コーポレイション | ピロロ[2,3−d]ピリミジン−4−イルおよびプリン−6−イル尿素化合物 |
US20060159617A1 (en) | 2002-11-08 | 2006-07-20 | Ashfaq Mahmood | Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors |
EP1568699A4 (en) | 2002-12-04 | 2007-08-15 | Eisai R&D Man Co Ltd | 1,3-DIHYDROIMIDAZOLE CONNECTION WITH CONDENSED RING |
US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
WO2004080463A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
WO2004094426A1 (en) | 2003-04-21 | 2004-11-04 | Ustav Organické Chemie A Biochemie Akademie Ved Ceské Republiky | (purin-6-yl) amino acid and production method thereof |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
EP1698375B1 (en) | 2003-12-25 | 2014-04-02 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
CA2590961C (en) | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
WO2006090129A2 (en) * | 2005-02-23 | 2006-08-31 | Astrazeneca Ab | Bicalutamide for delivering increasing steady state plasma levels |
RS52274B2 (sr) | 2005-05-13 | 2018-05-31 | Univ California | Jedinjenje diarilhidantoina |
US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
ES2719093T3 (es) | 2005-08-31 | 2019-07-08 | Abraxis Bioscience Llc | Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación |
TW200738709A (en) | 2006-01-19 | 2007-10-16 | Osi Pharm Inc | Fused heterobicyclic kinase inhibitors |
WO2007125315A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
JP2009534454A (ja) | 2006-04-25 | 2009-09-24 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
WO2007125310A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical combinations of pk inhibitors and other active agents |
WO2007125325A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
MX2009006700A (es) | 2006-12-21 | 2009-06-30 | Vertex Pharma | Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas. |
US20110312916A1 (en) * | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
WO2011029782A1 (en) * | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
BR112012027745A2 (pt) * | 2010-04-27 | 2017-01-10 | Univ Johns Hopkins | método e composição imunogênica para tratamento de neoplásia |
-
2012
- 2012-11-30 PT PT127958429T patent/PT2785349T/pt unknown
- 2012-11-30 MX MX2014006547A patent/MX367640B/es active IP Right Grant
- 2012-11-30 LT LT12795842T patent/LT2785349T/lt unknown
- 2012-11-30 HR HRP20191982TT patent/HRP20191982T4/hr unknown
- 2012-11-30 WO PCT/GB2012/052969 patent/WO2013079964A1/en active Application Filing
- 2012-11-30 CN CN201280059109.1A patent/CN103945849B/zh active Active
- 2012-11-30 HU HUE12795842A patent/HUE046667T2/hu unknown
- 2012-11-30 MY MYPI2014701394A patent/MY175800A/en unknown
- 2012-11-30 US US14/361,718 patent/US20140329786A1/en not_active Abandoned
- 2012-11-30 AU AU2012321110A patent/AU2012321110B2/en active Active
- 2012-11-30 DK DK12795842.9T patent/DK2785349T4/da active
- 2012-11-30 RS RS20191392A patent/RS59493B2/sr unknown
- 2012-11-30 FI FIEP12795842.9T patent/FI2785349T4/fi active
- 2012-11-30 CA CA2856646A patent/CA2856646C/en active Active
- 2012-11-30 PL PL12795842.9T patent/PL2785349T5/pl unknown
- 2012-11-30 JP JP2014543977A patent/JP6309454B2/ja active Active
- 2012-11-30 SG SG11201401471PA patent/SG11201401471PA/en unknown
- 2012-11-30 EP EP12795842.9A patent/EP2785349B2/en active Active
- 2012-11-30 RU RU2014119713A patent/RU2640485C2/ru active
- 2012-11-30 KR KR1020147016680A patent/KR102035361B1/ko active IP Right Grant
- 2012-11-30 SI SI201231690T patent/SI2785349T2/sl unknown
- 2012-11-30 ES ES12795842T patent/ES2762250T5/es active Active
-
2014
- 2014-05-08 IL IL232530A patent/IL232530B/en active IP Right Grant
-
2015
- 2015-03-18 HK HK15102783.0A patent/HK1202253A1/xx unknown
-
2016
- 2016-02-08 US US15/018,157 patent/US9737540B2/en active Active
-
2019
- 2019-12-17 CY CY20191101323T patent/CY1122624T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011500547A (ja) * | 2007-10-11 | 2011-01-06 | アストラゼネカ アクチボラグ | プロテインキナーゼb阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 |
WO2010092371A1 (en) * | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
Non-Patent Citations (6)
Title |
---|
BR. J. CANCER, vol. 103, no. 7, JPN6017021113, 2010, pages 1001 - 1007, ISSN: 0003575713 * |
CANCER RES., vol. 69, no. 18, JPN6017021110, 2009, pages 7466 - 7472, ISSN: 0003575710 * |
J. BIOL. CHEM., vol. 278, no. 51, JPN6017021111, 2003, pages 50902 - 50907, ISSN: 0003738945 * |
MOL. CANCER THER., vol. 7, no. 1, JPN6017021112, 2008, pages 121 - 132, ISSN: 0003575712 * |
PROSTATE CANCER, vol. 2011, JPN7016002361, October 2011 (2011-10-01), pages 918707 - 1, ISSN: 0003377633 * |
田畑 健一 KEN-ICHI TABATA KEN-ICHI TABATA: "分子標的治療 Molecular targeted therapy for castration -resistant prostate cancer", 日本臨床(別冊・増刊) 6月号, vol. 第69巻, JPN6017021114, 15 June 2011 (2011-06-15), pages 165 - 169, ISSN: 0003575711 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6309454B2 (ja) | 癌の併用処置 | |
US8697662B2 (en) | Methods for treating Kaposi sarcoma | |
KR102225371B1 (ko) | 플리나불린 및 탁산의 조합에 의한 암 치료 | |
JP2014132009A5 (ja) | ||
JP2020529996A5 (ja) | ||
JP2012500180A5 (ja) | ||
KR20150017367A (ko) | 종양 질환을 치료하기 위한 17-알파-히드록실라제 (c17,20-리아제) 억제제와 특이적 pi-3k 억제제의 조합물 | |
CA2682015A1 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
JP2019530648A5 (ja) | ||
US20210353648A1 (en) | Grapiprant unit dosage forms | |
JP2018135278A (ja) | 循環器疾患及び/又はミトコンドリア病の改善用医薬 | |
AU2013205648B2 (en) | Combination treatment | |
JP2020040892A (ja) | 肺高血圧治療薬 | |
JP2014231518A (ja) | 子宮腫瘍の治療用医薬の調製のための7−t−ブトキシイミノメチルカンプトテシンの使用 | |
JP2019001830A (ja) | 医薬 | |
NZ625611B2 (en) | Combination treatment of cancer | |
JP7445826B2 (ja) | 固形腫瘍治療用医薬組成物 | |
BR112014012261B1 (pt) | Combinação e uso de (s)-4-amino-n-(1-(4-clorofenil)-3- hidroxipropil)-1-(7h-pirrolo [2,3-d] pirimidin-4-il)piperidina-4- carboxamida com um modulador da sinalização do receptor de androgênio | |
WO2013051330A1 (ja) | ビダラビンによる心房細動治療 | |
TW202245742A (zh) | 預防、治療或改善潰瘍性結腸炎的方法 | |
TW202146007A (zh) | 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合 | |
KR20180037953A (ko) | 담관암을 위한 치료제 | |
JP2006117569A (ja) | ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160810 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160812 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180314 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6309454 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |